229 related articles for article (PubMed ID: 33775711)
21. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.
Jia Y; Yun CH; Park E; Ercan D; Manuia M; Juarez J; Xu C; Rhee K; Chen T; Zhang H; Palakurthi S; Jang J; Lelais G; DiDonato M; Bursulaya B; Michellys PY; Epple R; Marsilje TH; McNeill M; Lu W; Harris J; Bender S; Wong KK; Jänne PA; Eck MJ
Nature; 2016 Jun; 534(7605):129-32. PubMed ID: 27251290
[TBL] [Abstract][Full Text] [Related]
22. EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer.
Amato KR; Wang S; Tan L; Hastings AK; Song W; Lovly CM; Meador CB; Ye F; Lu P; Balko JM; Colvin DC; Cates JM; Pao W; Gray NS; Chen J
Cancer Res; 2016 Jan; 76(2):305-18. PubMed ID: 26744526
[TBL] [Abstract][Full Text] [Related]
23. Lamellarin 14, a derivative of marine alkaloids, inhibits the T790M/C797S mutant epidermal growth factor receptor.
Nishiya N; Oku Y; Ishikawa C; Fukuda T; Dan S; Mashima T; Ushijima M; Furukawa Y; Sasaki Y; Otsu K; Sakyo T; Abe M; Yonezawa H; Ishibashi F; Matsuura M; Tomida A; Seimiya H; Yamori T; Iwao M; Uehara Y
Cancer Sci; 2021 May; 112(5):1963-1974. PubMed ID: 33544933
[TBL] [Abstract][Full Text] [Related]
24. Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer.
Wang M; Zhao J; Zhang LM; Li H; Yu JP; Ren XB; Wang CL
J Cancer Res Clin Oncol; 2012 Dec; 138(12):2069-77. PubMed ID: 22821179
[TBL] [Abstract][Full Text] [Related]
25. Cetuximab Inhibits T790M-Mediated Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Lung Adenocarcinoma Patient-Derived Xenograft Mouse Model.
Martin P; Stewart E; Pham NA; Mascaux C; Panchal D; Li M; Kim L; Sakashita S; Wang D; Sykes J; Friess T; Shepherd FA; Liu G; Tsao MS
Clin Lung Cancer; 2016 Sep; 17(5):375-383.e2. PubMed ID: 26926157
[TBL] [Abstract][Full Text] [Related]
26. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
[TBL] [Abstract][Full Text] [Related]
27. Akt kinase LANCL2 functions as a key driver in EGFR-mutant lung adenocarcinoma tumorigenesis.
Lou Y; Xu J; Zhang Y; Zhang W; Zhang X; Gu P; Zhong H; Wang H; Lu J; Han B
Cell Death Dis; 2021 Feb; 12(2):170. PubMed ID: 33568630
[TBL] [Abstract][Full Text] [Related]
28. Reactivation of Mutant-EGFR Degradation through Clathrin Inhibition Overcomes Resistance to EGFR Tyrosine Kinase Inhibitors.
Ménard L; Floc'h N; Martin MJ; Cross DAE
Cancer Res; 2018 Jun; 78(12):3267-3279. PubMed ID: 29555874
[TBL] [Abstract][Full Text] [Related]
29. Vorinostat enhances gefitinib‑induced cell death through reactive oxygen species‑dependent cleavage of HSP90 and its clients in non‑small cell lung cancer with the EGFR mutation.
Park SE; Kim DE; Kim MJ; Lee JS; Rho JK; Jeong SY; Choi EK; Kim CS; Hwang JJ
Oncol Rep; 2019 Jan; 41(1):525-533. PubMed ID: 30365122
[TBL] [Abstract][Full Text] [Related]
30. Sequential use of EGFR-tyrosine kinase inhibitors based upon EGFR mutation evolution achieves long-term control in a non-small cell lung cancer patient: a case report.
Jiang Y; Zhang J; Jiang X; Cheng L; Liao X; Li Y; Zhang M; Chen R; Yin T
Ann Palliat Med; 2021 Jun; 10(6):7051-7056. PubMed ID: 33548986
[TBL] [Abstract][Full Text] [Related]
31. Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M,
Chang Y; Liu S; Jiang Y; Hua L; Wen L
Respir Med Case Rep; 2022; 36():101582. PubMed ID: 35106279
[TBL] [Abstract][Full Text] [Related]
32. Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer.
Song HN; Jung KS; Yoo KH; Cho J; Lee JY; Lim SH; Kim HS; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Park W; Ahn MJ
J Thorac Oncol; 2016 Apr; 11(4):e45-7. PubMed ID: 26749488
[TBL] [Abstract][Full Text] [Related]
33. Quantitative targeted proteomic analysis of potential markers of tyrosine kinase inhibitor (TKI) sensitivity in EGFR mutated lung adenocarcinoma.
Awasthi S; Maity T; Oyler BL; Qi Y; Zhang X; Goodlett DR; Guha U
J Proteomics; 2018 Oct; 189():48-59. PubMed ID: 29660496
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis and biological evaluation of phosphoroxy quinazoline derivatives as potential EGFR
Guo Y; Gao B; Gao P; Wang Y; Gou S
Bioorg Med Chem; 2023 Jul; 90():117338. PubMed ID: 37269687
[TBL] [Abstract][Full Text] [Related]
35. Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance Induced by Membranous/Cytoplasmic/Nuclear Translocation of Epidermal Growth Factor Receptor.
Rong X; Liang Y; Han Q; Zhao Y; Jiang G; Zhang X; Lin X; Liu Y; Zhang Y; Han X; Zhang M; Luo Y; Li P; Wei L; Yan T; Wang E
J Thorac Oncol; 2019 Oct; 14(10):1766-1783. PubMed ID: 31228625
[TBL] [Abstract][Full Text] [Related]
36. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
Lou W; Chen Y; Zhu KY; Deng H; Wu T; Wang J
Biol Pharm Bull; 2017 Aug; 40(8):1306-1313. PubMed ID: 28515374
[TBL] [Abstract][Full Text] [Related]
37. Discovery and structural optimization of potent epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M/C797S resistance mutation for lung cancer treatment.
Wang C; Wang X; Huang Z; Wang T; Nie Y; Yang S; Xiang R; Fan Y
Eur J Med Chem; 2022 Jul; 237():114381. PubMed ID: 35447433
[TBL] [Abstract][Full Text] [Related]
38. Conformational Constrained 4-(1-Sulfonyl-3-indol)yl-2-phenylaminopyrimidine Derivatives as New Fourth-Generation Epidermal Growth Factor Receptor Inhibitors Targeting T790M/C797S Mutations.
Chen H; Lai M; Zhang T; Chen Y; Tong L; Zhu S; Zhou Y; Ren X; Ding J; Xie H; Lu X; Ding K
J Med Chem; 2022 May; 65(9):6840-6858. PubMed ID: 35446588
[TBL] [Abstract][Full Text] [Related]
39. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
[TBL] [Abstract][Full Text] [Related]
40. Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, and
Zhao J; Zou M; Lv J; Han Y; Wang G; Wang G
Onco Targets Ther; 2018; 11():5545-5550. PubMed ID: 30233215
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
